Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + intensity modulated radiation therapy
- Development stage
- Unknown
- Lead developer
- University of Michigan Rogel Cancer Center
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This therapeutic regimen combines the chemotherapy agent gemcitabine with intensity-modulated radiotherapy (IMRT), specifically investigated by the University of Michigan Rogel Cancer Center for the treatment of unresectable pancreatic adenocarcinoma. Gemcitabine is a nucleoside analog that inhibits DNA synthesis by targeting ribonucleotide reductase and competing with deoxycytidine triphosphate for incorporation into DNA by DNA polymerase. In this specific Phase I/II trial context, gemcitabine is administered at a fixed-dose rate (1000 mg/m²) concurrently with dose-escalated IMRT to improve local control and survival in patients with locally advanced, unresectable disease. The regimen leverages the radiosensitizing properties of gemcitabine to enhance the efficacy of targeted radiation delivery.
- Brand names
- Gemzar
- Other names
- gemcitabine + IMRTIMRT with concurrent gemcitabinefixed-dose rate gemcitabine plus IMRT
02
Targets
DNA polymerase familyRNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on gemcitabine + intensity modulated radiation therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + intensity modulated radiation therapy.